A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days. - Related Studies

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.

This study has been completed.

Study NCT00002138. Last updated on June 23, 2005. Information provided by NIH AIDS Clinical Trials Information Service

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Sarcoma, Kaposi
		HIV Infections

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Infection
		Sarcoma

3	More general conditions related to this trial
		DNA Virus Infections
		Herpesviridae Infections
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms, Connective and Soft Tissue
		Neoplasms, Vascular Tissue
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Tecogalan sodium

5	Sponsors listed in this trial
		Daiichi Pharmaceuticals